Skip to content
Bored Studies
RecruitingPhase 2

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Eli Lilly and Company · NCT07783802

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
120
US sites recruiting
29
Study start
August 27, 2026
Record last updated
October 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event.

Participation in the study will last about 9 months.

Being studied: Clazakizumab; Placebo

Conditions: Atherosclerosis; Cardiovascular Disease; Obesity; Hypertension; Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • hsCRP ≥2 mg/L and ≤15 mg/L at screening
  • At least one of the following chronic conditions:
  • Established atherosclerotic cardiovascular disease (ASCVD)
  • Obesity (body mass index (BMI) ≥30 kg/m2)
  • Type 2 diabetes
  • Hypertension
  • Chronic kidney disease Grade 3 or 4

Exclusion Criteria

  • Acute cardiovascular event within 60 days prior to screening
  • Acute decompensated heart failure hospitalization within 60 days prior to screening
  • Planned coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or major surgery at the time of randomization
  • New York Heart Association Class III or IV heart failure
  • Uncontrolled hypertension at screening (systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg)
  • Type 1 diabetes
  • Type 2 diabetes with Hemoglobin A1c ≥9.0% (86 mmol/mol) at screening
  • Nephrotic syndrome, estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m², or history of kidney transplant
  • Dialysis or acute kidney injury within 60 days prior to screening
  • Congenital/hereditary kidney disease, polycystic kidney disease, lupus nephritis, or antineutrophil cytoplasmic antibody-associated vasculitis
  • Active tuberculosis, untreated latent tuberculosis, or known hepatitis B or hepatitis C infection
  • Serious, opportunistic, chronic, or recurrent infection requiring treatment within 12 weeks prior to screening
  • Significant active autoimmune disease
  • Suspected or confirmed immunocompromised state (e.g., HIV infection)
  • History of peptic ulcer disease or gastrointestinal ulceration within 12 months prior to screening
  • History of symptomatic diverticular disease (diverticulitis), gastrointestinal perforation, or major gastrointestinal surgery
  • Mechanical heart valve prosthesis requiring chronic vitamin K antagonist anticoagulation
  • Use of colchicine within 14 days prior to screening or anticipated need during the study
  • Use of immunosuppressive or immunomodulatory agents, including other biologic anti-IL-6 therapies, within specified windows prior to screening
  • Use of systemic corticosteroids within 14 days prior to screening
  • Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs)

Recruiting US locations

  • Heart Center Research, LLC

    Huntsville, AL 35801

    Site contact: 256-519-8472

  • Pima Heart

    Tucson, AZ 85741

    Site contact: 717-615-0659

  • Eclipse Clinical Research

    Tucson, AZ 85745

    Site contact: 520-647-9926

  • Thrive Clinical Research Group

    Glendora, CA 91740

    Site contact: 626-727-7254

  • Omega Research Orlando

    Altamonte Springs, FL 32714

    Site contact: 386-668-4202

  • American Research Institute

    Cutler Bay, FL 33157

    Site contact: Manuel Garcia Estrada

  • K2 Medical Research - Maitland

    Maitland, FL 32751

    Site contact: 407-810-2790

  • Florida Institute For Clinical Research, LLC

    Orlando, FL 32825

    Site contact: 407-658-0966

  • North Georgia Clinical Research

    Woodstock, GA 30189

    Site contact: 678-494-5735

  • Franciscan Physician Network - Indiana Heart Physicians

    Indianapolis, IN 46237

    Site contact: Anthony Bashall

  • K2 Medical Research - Foxborough

    Foxborough, MA 02035

    Site contact: Daniel Sacchetti

  • Revival Research Institute, LLC

    Dearborn, MI 48126

    Site contact: Qaiser Shafiq

  • Olive Branch Family Medical Center

    Olive Branch, MS 38654-3514

    Site contact: 662-893-8474

  • Excel Clinical Research, LLC

    Las Vegas, NV 89109

    Site contact: 702-680-1500

  • Palm Research Center Tenaya

    Las Vegas, NV 89128

    Site contact: 702-736-5161

  • Rochester Clinical Research - Buffalo

    Buffalo, NY 14217

    Site contact: 716-415-8380

  • CHEAR Center LLC

    The Bronx, NY 10455

    Site contact: 347-270-1111

  • Velocity Clinical Research, Cincinnati, Springdale

    Cincinnati, OH 45246

    Site contact: 513-671-8080

  • Suburban Research Associates

    West Chester, PA 19380

    Site contact: Omer Abdullah

  • Cardiology Consultants of Philadelphia Yardley

    Yardley, PA 19067

    Site contact: 215-321-7400

  • Monroe Biomedical Research - Charleston

    North Charleston, SC 29406

    Site contact: 803-766-2680

  • Horizon Clinical Research Group

    Cypress, TX 77429

    Site contact: 949-491-0710

  • Cardiovascular Specialists of Willowbrook

    Houston, TX 77070

    Site contact: 949-491-0710

  • Texas Cardiology Associates of Houston

    Kingwood, TX 77339

    Site contact: Robert Salazar

  • Revival Research Institute, LLC

    McKinney, TX 75071

    Site contact: Asad Karim

  • Texas Institute of Cardiology, PA

    McKinney, TX 75071

    Site contact: 214-544-7555

  • Ogden Clinic - Canyon View

    Ogden, UT 84404

    Site contact: 385-271-0684

  • Carient Heart & Vascular - Manassas

    Manassas, VA 20109

    Site contact: 703-335-8750

  • Carient Heart and Vascular LLC-Reston

    Reston, VA 20190

    Site contact: Adeeb Aghdassi

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All weight loss studies in Alabama →
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP… (NCT07783802) | Bored Studies